LAG-3 in cancer immunotherapy

Monica V. Goldberg, Charles G. Drake

Research output: Contribution to journalArticle

Abstract

LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885- 1891, 2009) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874-3880, 2002). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29-37, 2009), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)269-278
Number of pages10
JournalCurrent Topics in Microbiology and Immunology
Volume344
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Immunotherapy
Dendritic Cells
T-Lymphocytes
Immunogenetics
Lymphocyte Subsets
Natural Killer Cells
Neoplasms
B-Lymphocytes
Clinical Trials
Ligands
Proteins

Keywords

  • Anergy
  • CD4 lymphocyte
  • CD8 lymphocyte
  • Checkpoint
  • LAG-3
  • Tolerance
  • Treg
  • Tumor immunology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Microbiology (medical)
  • Immunology
  • Microbiology

Cite this

LAG-3 in cancer immunotherapy. / Goldberg, Monica V.; Drake, Charles G.

In: Current Topics in Microbiology and Immunology, Vol. 344, No. 1, 2010, p. 269-278.

Research output: Contribution to journalArticle

Goldberg, Monica V. ; Drake, Charles G. / LAG-3 in cancer immunotherapy. In: Current Topics in Microbiology and Immunology. 2010 ; Vol. 344, No. 1. pp. 269-278.
@article{1b8a407454654a7aa6570a82e4ab371a,
title = "LAG-3 in cancer immunotherapy",
abstract = "LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885- 1891, 2009) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874-3880, 2002). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29-37, 2009), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.",
keywords = "Anergy, CD4 lymphocyte, CD8 lymphocyte, Checkpoint, LAG-3, Tolerance, Treg, Tumor immunology",
author = "Goldberg, {Monica V.} and Drake, {Charles G.}",
year = "2010",
doi = "10.1007/82-2010-114",
language = "English (US)",
volume = "344",
pages = "269--278",
journal = "Current Topics in Microbiology and Immunology",
issn = "0070-217X",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - LAG-3 in cancer immunotherapy

AU - Goldberg, Monica V.

AU - Drake, Charles G.

PY - 2010

Y1 - 2010

N2 - LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885- 1891, 2009) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874-3880, 2002). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29-37, 2009), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.

AB - LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885- 1891, 2009) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874-3880, 2002). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29-37, 2009), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.

KW - Anergy

KW - CD4 lymphocyte

KW - CD8 lymphocyte

KW - Checkpoint

KW - LAG-3

KW - Tolerance

KW - Treg

KW - Tumor immunology

UR - http://www.scopus.com/inward/record.url?scp=84862865552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862865552&partnerID=8YFLogxK

U2 - 10.1007/82-2010-114

DO - 10.1007/82-2010-114

M3 - Article

VL - 344

SP - 269

EP - 278

JO - Current Topics in Microbiology and Immunology

JF - Current Topics in Microbiology and Immunology

SN - 0070-217X

IS - 1

ER -